Lim Seah H. 4

4 · Emmaus Life Sciences, Inc. · Filed Dec 19, 2023

Form 4

Period: 2022-10-09

Director

Transactions

Purchase
Common stock, $0.001 par value
2023-08-30$0.15/sh+20,000$3,000→ 176,000 total
Purchase
Common stock, $0.001 par value
2023-09-05$0.15/sh+1,700$255→ 177,700 total
Sale
Common stock, $0.001 par value
2023-12-15$0.11/sh−6,000$660→ 171,700 total
Other
Common stock, $0.001 par value
2023-12-15$0.29/sh+4,447,426$1,289,754→ 4,619,126 total
Purchase
Common stock, $0.001 par value
2023-08-25$0.27/sh+92,100$24,867→ 156,000 total
Purchase
Common stock, $0.001 par value
2022-10-09$0.11/sh+25,400$2,794→ 63,900 total
Other
Promissory Note due 9/16/2025
2023-12-15−240,000→ 0 total
Exercise: $0.29→ Common Stock (240,000 underlying)

Footnotes (4)

[F1]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.20 to $0.27, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).
[F2]The shares shown were issued in exchange for principal and accrued interest under the promissory note of the Issuer held by the reporting person referred to in footnote (2), below, which promissory note was surrendered by the reporting person for cancellation.
[F3]Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above.
[F4]Represent shares previously issuable upon maturity of the Promissory Note due 9/16/2025.

Documents

1 file